At AACR 2026, several first-time disclosed oncology programs highlighted how public biotech and pharma companies are positioning for the next wave of innovation. From an investor perspective, the key question remains: Does this asset improve the company’s position in a real, competitive market? Below is a focused look at newly disclosed assets from public companies, through four lenses: disease target, competition, technology, and potential market impact. 🟢 AstraZeneca: Prec